Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced ...
Lisa Taylor Ash joins Board of Directors, strengthening operational, regulatory and commercial expertise DUBLIN and LONDON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results